These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1859896)

  • 21. [Dissociation between the effect on myeloblastoma and the hematologic effect of Ara-C therapy: report of an autopsied myeloblastic leukemia case with around five-year course].
    Koyama T; Tohda S; Kamiyama T; Suzuki T; Nagata K; Nakamura Y; Miura O; Maruyama Y; Kato A; Murakami N
    Rinsho Ketsueki; 1988 Dec; 29(12):2302-6. PubMed ID: 3246715
    [No Abstract]   [Full Text] [Related]  

  • 22. Improving the "quality of remission induction" therapy: a necessary step for increasing the cure rate in acute myelogenous leukemia.
    Arlin ZA; Feldman E; Finger L; Decter J; Cook P; Ahmed T; Puccio C; Chun H; Mittelman A
    Cancer Invest; 1992; 10(2):183-4. PubMed ID: 1551027
    [No Abstract]   [Full Text] [Related]  

  • 23. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients.
    Preisler H; Raza A; Larson R; Goldberg J; Tricot G; Carey M; Kukla C
    Leuk Res; 1991; 15(9):773-80. PubMed ID: 1921456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of clonogenic leukemic cell characteristics to therapy outcome in patients with acute myeloblastic leukemia.
    Aul C; Heyll A
    Haematol Blood Transfus; 1987; 30():356-60. PubMed ID: 3476367
    [No Abstract]   [Full Text] [Related]  

  • 25. Aclacinomycin-A in the induction treatment of childhood acute myelogenous leukemia.
    Fink FM; Grümayer ER; Kardos G; Revesz T; Gadner H; Schuler D
    Haematol Blood Transfus; 1987; 30():393-8. PubMed ID: 3305209
    [No Abstract]   [Full Text] [Related]  

  • 26. Cellular pharmacokinetics of daunomycin in human leukemic blasts in vitro and in vivo.
    Scheulen ME; Kramer B; Skorzec M; Reich WK
    Haematol Blood Transfus; 1990; 33():122-8. PubMed ID: 2323624
    [No Abstract]   [Full Text] [Related]  

  • 27. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults.
    Phillips GL; Reece DE; Shepherd JD; Barnett MJ; Brown RA; Frei-Lahr DA; Klingemann HG; Bolwell BJ; Spinelli JJ; Herzig RH
    Blood; 1991 Apr; 77(7):1429-35. PubMed ID: 2009367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy of acute myelogenous leukemia in adults.
    Petti MC; Broccia G; Caronia F; Di Raimondo F; Fioritoni G; Ladogana S; Leone G; Liso V; Musso M; Neri A
    Haematol Blood Transfus; 1990; 33():249-53. PubMed ID: 2182417
    [No Abstract]   [Full Text] [Related]  

  • 29. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
    Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
    Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased tumor growth and drug uptake predicts for response to continuous infusion high-dose cytarabine.
    Burke PJ; Karp JE
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):55-9. PubMed ID: 3859933
    [No Abstract]   [Full Text] [Related]  

  • 31. Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
    Zittoun R; Mandelli F; Willemze R; de Witte T; Tura S; Ferrini PR; Stryckmans P; Gattringer C; Petti MC; Solbu G
    Leukemia; 1992; 6 Suppl 2():114-5. PubMed ID: 1578909
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
    Schiller G; Gajewski J; Territo M; Nimer S; Lee M; Belin T; Champlin R
    Blood; 1992 Dec; 80(12):2977-82. PubMed ID: 1467513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative analysis of 3 therapeutic regimens based on the combination of an anthracycline and cytosine arabinoside for remission induction in myeloblastic leukemia].
    Sanz MA; Lorenzo JI; Sanz GF; Martín Aragonés G; Rafecas FJ; Martínez JA; Gomis F
    Sangre (Barc); 1988 Dec; 33(6):497-504. PubMed ID: 3247626
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation.
    Champlin R; Ho W; Winston D; Decker R; Greenberg P; Burnison M; Holly FE; Gale RP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):1-6. PubMed ID: 2438775
    [No Abstract]   [Full Text] [Related]  

  • 35. A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia.
    Kurrle E; Ehninger G; Freund M; Heil G; Hoelzer D; Link H; Mitrou PS; Ohl S; Queisser W; Schlimok G
    Blut; 1988 May; 56(5):233-6. PubMed ID: 3285914
    [No Abstract]   [Full Text] [Related]  

  • 36. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
    Wiernik PH; Case DC; Periman PO; Arlin ZA; Weitberg AB; Ritch PS; Todd MB
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):25-9. PubMed ID: 2928807
    [No Abstract]   [Full Text] [Related]  

  • 37. Intensive sequential chemotherapy for children with acute myelogenous leukemia.
    Grier HE; Gelber RD; Clavell LA; Camitta BM; Link MP; Garcea MJ; Weinstein HJ
    Haematol Blood Transfus; 1990; 33():193-7. PubMed ID: 2182411
    [No Abstract]   [Full Text] [Related]  

  • 38. [A case of refractory acute myeloblastic leukemia who achieved partial remission by high dose cytosine arabinoside].
    Okamoto S; Ogata H; Yoshida T; Oheda Y; Murase T; Toyama K
    Rinsho Ketsueki; 1984 May; 25(5):719-23. PubMed ID: 6590900
    [No Abstract]   [Full Text] [Related]  

  • 39. [Cancer curable by chemotherapy: acute myelogenous leukemia].
    Ohno R; Tanimoto M; Morishita Y; Morishima Y; Saito H; Yokomaku S; Nagai T; Kodera Y; Minami S
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1329-34. PubMed ID: 2730046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
    Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
    Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.